130 related articles for article (PubMed ID: 11384805)
1. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.
Gokmen O; Ugur M; Ekin M; Keles G; Turan C; Oral H
Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):187-92. PubMed ID: 11384805
[TBL] [Abstract][Full Text] [Related]
2. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
Youssef MA; Mourad S
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
[TBL] [Abstract][Full Text] [Related]
3. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.
Youssef MA; Al-Inany HG; Evers JL; Aboulghar M
Cochrane Database Syst Rev; 2011 Feb; (2):CD001302. PubMed ID: 21328249
[TBL] [Abstract][Full Text] [Related]
4. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch.
Matorras R; Andrés M; Mendoza R; Prieto B; Pijoan JI; Expósito A
Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):439-43. PubMed ID: 23932181
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.
Shaker AG; Zosmer A; Dean N; Bekir JS; Jacobs HS; Tan SL
Fertil Steril; 1996 May; 65(5):992-6. PubMed ID: 8612863
[TBL] [Abstract][Full Text] [Related]
6. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.
Isik AZ; Gokmen O; Zeyneloglu HB; Kara S; Keles G; Gulekli B
Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(2):179-83. PubMed ID: 9119100
[TBL] [Abstract][Full Text] [Related]
7. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study.
König E; Bussen S; Sütterlin M; Steck T
Hum Reprod; 1998 Sep; 13(9):2421-4. PubMed ID: 9806261
[TBL] [Abstract][Full Text] [Related]
9. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme.
Graf MA; Fischer R; Naether OG; Baukloh V; Tafel J; Nückel M
Hum Reprod; 1997 Dec; 12(12):2599-602. PubMed ID: 9455820
[TBL] [Abstract][Full Text] [Related]
10. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
[TBL] [Abstract][Full Text] [Related]
11. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.
Shoham Z; Weissman A; Barash A; Borenstein R; Schachter M; Insler V
Fertil Steril; 1994 Jul; 62(1):137-42. PubMed ID: 8005278
[TBL] [Abstract][Full Text] [Related]
12. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome.
Isik AZ; Vicdan K
Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):208-12. PubMed ID: 11451550
[TBL] [Abstract][Full Text] [Related]
13. Embryo freezing for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2007 Jul; (3):CD002806. PubMed ID: 17636707
[TBL] [Abstract][Full Text] [Related]
14. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
15. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?
Ndukwe G; Thornton S; Fishel S; Dowell K; Aloum M
Fertil Steril; 1997 Nov; 68(5):851-4. PubMed ID: 9389814
[TBL] [Abstract][Full Text] [Related]
16. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
17. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.
Bellver J; Muñoz EA; Ballesteros A; Soares SR; Bosch E; Simón C; Pellicer A; Remohí J
Hum Reprod; 2003 Nov; 18(11):2283-8. PubMed ID: 14585874
[TBL] [Abstract][Full Text] [Related]
18. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
19. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome.
Chen CD; Chao KH; Yang JH; Chen SU; Ho HN; Yang YS
Fertil Steril; 2003 Jul; 80(1):86-90. PubMed ID: 12849806
[TBL] [Abstract][Full Text] [Related]
20. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
